Johnson & Johnson’s and AbbVie’s cancer drug Imbruvica significantly reduced the risk of death and disease progression compared with chemotherapy in previously untreated patients with a type of leukemia in a late stage study, paving the way for an expanded approval of the medicine. In the trial of 269 patients aged 65 and older with chronic lymphocytic leukemia (CLL), Imbruvica decreased risk of death by a statistically significant 85 percent compared with the chemotherapy chlorambucil, researchers reported on Sunday.
Excerpt from:
J&J leukemia drug cuts death risk vs. chemo in new patients: study